Keros Therapeutics, Inc. filings document a clinical-stage biopharmaceutical issuer developing therapeutics that modulate transforming growth factor-beta family signaling. Its 8-K reports cover financial results, Regulation FD corporate presentations, clinical-program announcements, collaboration disclosures, and board composition changes, while exchange registration disclosures identify Nasdaq-listed common stock and preferred share purchase rights.
The company’s proxy materials describe stockholder voting matters, board and committee governance, director compensation, and executive compensation. They also disclose portfolio strategy, including prioritization of rinvatercept, discontinued internal development activities for cibotercept, and related governance oversight of the company’s research and development focus.
Keros Therapeutics ownership disclosure: Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, report beneficial ownership of 1,360,419 shares of Common Stock, representing 6.90% of shares outstanding as of March 31, 2026. The filing states shared voting and dispositive power over these shares.
Keros Therapeutics reported a return to losses in early 2026 as one-time licensing revenue rolled off and it resumed a more typical R&D-focused profile. For the three months ended March 31, 2026, total revenue was $0.4 million, almost entirely from service and supply work under its Takeda and Hansoh collaborations, compared with $211.2 million a year earlier when it booked a large upfront license payment from Takeda.
Research and development expenses fell sharply to $16.1 million from $48.7 million as elritercept costs transitioned to Takeda, the cibotercept program wound down and prior restructuring reduced headcount. General and administrative costs were stable at $10.1 million. The company recorded a net loss of $23.7 million, or $1.21 per share, versus net income of $148.5 million, or $3.66 per share, in the prior-year quarter.
Keros ended the period with $281.5 million in cash and cash equivalents and $275.1 million of that in money market funds, and believes this balance will fund operations for at least 12 months. The business remains clinical-stage with no product sales, centered on rinvatercept for Duchenne muscular dystrophy and amyotrophic lateral sclerosis, and partnered elritercept for blood disorders. The company plans to start a Phase 2 trial of rinvatercept in Duchenne muscular dystrophy in the third quarter of 2026 and aims to share initial data in the first half of 2027.
Keros Therapeutics reported a net loss of $23.7 million for the quarter ended March 31, 2026, compared with net income of $148.5 million a year earlier. The swing mainly reflects the absence of large license revenue recognized in 2025 from its agreement with Takeda and lower research and development activity.
Revenue fell to $0.4 million from $211.2 million, while research and development expenses declined to $16.1 million from $48.7 million as elritercept costs shifted to Takeda and a 2025 corporate restructuring reduced spending. General and administrative expenses were stable at $10.1 million. Keros ended the quarter with cash and cash equivalents of $281.5 million and expects this to fund operations into the first half of 2028, while its partner Takeda plans to advance elritercept into a Phase 3 trial for anemia in myelofibrosis.
Keros Therapeutics calls its 2026 annual meeting for June 3, 2026, asking stockholders to elect two Class III directors, ratify Deloitte & Touche LLP as auditor for 2026, and approve an advisory “say‑on‑pay” vote on executive compensation.
The proxy also describes a major strategic realignment in 2025, with Keros discontinuing material internal development of cibotercept to focus on its lead program, rinvatercept, targeting Duchenne muscular dystrophy and other neuromuscular diseases. The company highlights encouraging Phase 1 data, plans for Phase 2 trials in DMD and ALS, and an ALS collaboration within the Healey ALS MyMatch program.
Keros reports completing a $375 million capital return program through share repurchases, including a tender offer, while indicating it preserved flexibility to fund key clinical priorities. The filing outlines ongoing board refreshment, recent director changes and an independent chair structure, alongside detailed descriptions of board committees, governance practices and stockholder voting mechanics.
Keros Therapeutics director Jean Jacques Bienaimé made an open-market purchase of the company’s common stock. On April 15, 2026, he bought 1,000 shares at a weighted average price of $11.70 per share, increasing his direct holdings to 8,450 shares.
The shares were purchased under a Rule 10b5-1 trading plan that Bienaimé adopted on December 5, 2025. The filing notes the trade was executed through multiple transactions at prices between $11.56 and $11.80 per share.
Keros Therapeutics Schedule 13G reports that BlackRock, Inc. beneficially owned 1,990,842 shares of common stock, representing 10.1% of the class as of 03/31/2026. The filing attributes ownership to certain Reporting Business Units of BlackRock and shows 1,960,306 shares with sole voting power.
The filing states that various persons may have rights to dividends or sale proceeds and that no single outside person holds more than 5% separately. The filing is signed by a BlackRock managing director on 04/07/2026.
Keros Therapeutics chief executive officer Jasbir Seehra exercised employee stock options to acquire 55,000 shares of common stock at an exercise price of $0.30 per share on April 2, 2026. These options were immediately exercisable. Following the transaction, he directly owned 440,708 shares of common stock.
Keros Therapeutics reported that Chief Legal Officer Esther Cho received a grant of employee stock options covering 80,000 shares of common stock. The options have an exercise price of $15.52 per share and expire on February 23, 2036. One quarter of the options vest on February 24, 2027, with the remaining shares vesting in twelve substantially equal quarterly installments, contingent on her continued service. This is a compensation-related award rather than an open‑market purchase.